Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube
Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Fineline Cube
Company Drug

Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic

Fineline Cube

You Missed

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Company Drug

Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Digital Drug

ReviR Therapeutics Doses First Patient in RTX-117 Trial – China’s First “AI + RNA” Small Molecule Enters Clinic